Moogene Medi Co., Ltd. (XKON:322970)
South Korea · Delayed Price · Currency is KRW 2,075.00
+50.00 (2.47%)
At close: Aug 1, 2025, 3:30 PM KST
Moogene Medi Company Description
Moogene Medi Co., Ltd. develops gene therapies based on its proprietary gene-editing platform technology.
The company’s product portfolio comprises MG-001, which is in Phase I clinical trials to treat colon cancer; MG-002 that is in preclinical stage for use in the treatment of pancreatic cancer; and MG-003, which is in preclinical stage for use in the treatment of diabetes mellitus.
Its research stage products include MG-004 for treating hair loss and MG-005 for use in the treatment of Crohn's disease.
The company was founded in 2016 and is based in Hanam-si, South Korea.
Moogene Medi Co., Ltd.
| Country | South Korea |
| Founded | 2016 |
| Industry | Biological Products, Except Diagnostic Substances |
Contact Details
Address: Building C Hanam-si, 12939 South Korea | |
| Phone | 82 31 8027 6150 |
| Website | moogene.com |
Stock Details
| Ticker Symbol | 322970 |
| Exchange | Korea New Exchange |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |